Work

Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps5100

Authors: Jones T. Nauseef, Joseph Osborne, Peter Gregos, Charlene Thomas, Mahelia Bissassar, Sharon Singh, Amie Patel, Angela Tan, Muhammad Obaid Naiz, Juana Martinez Zuloaga, Tessa Chamberlain, Kara Earle, Rebecca Wunder, Himanshu Nagar, Ana M. Molina, Cora N. Sternberg, David M. Nanus, Neil Harrison Bander, Scott T. Tagawa

Institutions: NewYork–Presbyterian Hospital, Weill Cornell Medical Center, Weill Cornell Medicine

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Institutes of Health, Weill Cornell Medical College

OpenAlex ID: W4281688546

Cites:

Cited by: 5

Related to: 10